The Zemaira Difference

Zemaira raises alpha₁ antitrypsin levels

Zemaira is approved by the FDA for chronic augmentation and maintenance therapy in adults with Alpha-1 and emphysema. CSL Behring is with you every step of the way, offering Alpha-1 patients the support of the CareZ community, a comprehensive suite of services that helps make access to treatment easier.

The benefits of Zemaira

Zemaira provides the range of benefits you expect from an alpha₁ antitrypsin augmentation therapy. Select a benefit below to learn more:

EFFICACY

Proven in clinical trials to raise and maintain therapeutic levels of alpha₁ antitrypsin
- Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available

PURITY

The first highly purified alpha₁ antitrypsin augmentation therapy approved by the FDA
Rigorous purification process helps remove unwanted and unnecessary substances
- Helps reduce the risk of virus transmission
The possibility of transmission of infectious agents cannot be completely eliminated

SAFETY

In clinical trials, the majority of side effects were considered to be mild
- 1% of subjects reported the following mild adverse reactions:
  - Fatigue
  - Injection-site pain
  - Dizziness
  - Headache
  - Tingling
  - Itching

DOSING CONVENIENCE

Low volume of 20 mL requires only 15 minutes to infuse*
Can be stored safely at room temperature
Easy to reconstitute
The recommended dosage of Zemaira is 60 mg/kg body weight once a week

*Based on recommended dosage, as stated in the product package insert, of 60 mg/kg body weight at an infusion rate of 0.08 mL/kg/min.

Talking With Your Doctor

Connect to CareZ™

A community that offers comprehensive support services for patients with Alpha-1

Do I Have Alpha-1?

A simple questionnaire that encourages patients to talk to their doctor about getting tested for Alpha-1

Important Safety Information

Alpha₁-Proteinase Inhibitor (Human), Zemaira^® is indicated to raise the plasma level of alpha₁-proteinase inhibitor (A₁-PI) in patients with A₁-PI deficiency and related emphysema. The effect of this raised level on the frequency of pulmonary exacerbations and the progression of emphysema have not been established in clinical trials.

Zemaira may not be suitable for everyone; for example, people with known hypersensitivity to components used to make Zemaira, those with a history of anaphylaxis or severe systemic response to A₁-PI products, and those with certain IgA deficiencies. If you think any of these may apply to you, ask your doctor.

Early signs of hypersensitivity reactions to Zemaira include hives, rash, tightness of the chest, unusual breathing difficulty, wheezing, and feeling faint. Immediately discontinue use and consult with physician if such symptoms occur.

In clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving Zemaira: headache, sinusitis, upper respiratory infection, bronchitis, fatigue, increased cough, fever, injection-site bleeding, nasal symptoms, sore throat, and swelled blood vessels.

Because Zemaira is made from human blood, the risk of transmitting infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information for Zemaira.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.